| |
Creutzfeldt-Jakob disease (CJD) and kuru are the human disease forms
of a spectrum of infectious animal diseases (eg, scrapie in sheep, and
bovine spongiform encephalopathy [BSE]) which currently feature on
the front pages of most daily newspapers in Europe.
In the 1950s, Australia played a pivotal role in describing kuru in
Papua New Guinea.1 This devastating illness
was caused by transmission of infectivity from human-to-human
through cannibalistic mourning rituals involving infected brain
tissue. At the peak of the kuru epidemic, more than 5% of the population
practising these rituals died each year. The more recent
agricultural practice of supplementing ruminant feeds with protein
derived from bovine meat and bone meal (a practice differing in no
substantial way from cannibalism) has resulted in the
bovine-to-bovine cycle of transmission of BSE, a particularly
virulent strain of this infectious protein. It is now clear that BSE
has crossed the bovine-human species barrier, and that the result is
the variant form of CJD (vCJD) in humans.2
The next year or so may be crucial in estimating the likely extent of the
epidemic of vCJD in Europe. Last year, the number of new cases in the
United Kingdom grew at the disturbing rate of 30%3 (yielding a
total of more than 90 cases since the epidemic commenced in 1995), and
there were approximately 20 deaths from vCJD. The source of this human
pathogen has been convincingly linked to the preceding outbreak of
BSE, with transmission occurring orally. Unlike the classical forms
of sporadic CJD, the vCJD strain has a propensity for replication in
peripheral lymphoreticular tissue.
Although the UK outbreak of BSE is now almost under control, the same
can not be said for the rest of Europe, where recent evidence suggests
that increasing numbers (albeit from a low base) of affected cattle
are to be expected in France, Germany, Switzerland, Portugal and the
Republic of Ireland (Box).4 As more sensitive
biochemical assays become available for the detection of the
disease-associated forms of the prion protein (PrPSc), it is likely that subclinical forms of
BSE will be detected. Australia's monitoring program includes
examination of diseased cattle, but there is as yet no random
sampling. Ruminant protein is prohibited from entering the feed of
ruminants.
In the United Kingdom, the regulatory authorities have taken
unprecedented steps to reduce the risks of transmission of BSE from
cattle. These include severe restrictions on all feeding of
mammalian proteins to ruminants, severe restrictions on specified
bovine and ovine offals entering the human food chain, and a ban on
cattle over 30 months of age entering the human food chain. Further
measures will be introduced to minimise the risks of establishing a
reservoir of self-sustaining human-to-human infectivity,
including:
- universal leukodepletion of all blood donations;
- cessation of use of UK-sourced plasma for the preparation of
licensed blood products (eg, coagulation factors, albumin);
- increased levels of decontamination of surgical instruments,
especially those used for neurosurgery and ophthalmic surgery;
- increased use of disposable surgical instruments, initially for
tonsillectomies, but possibly extending to other equipment which
comes into direct contact with tissues of known high infectivity
(central nervous system, ophthalmic tissues, lymphoreticular
system).
The Australian responses to this new threat have been cumulative and
consistent with measures that have been progressively introduced in
other countries that remain BSE-free. Surveillance mechanisms are
in place to monitor the occurrence of classical forms of CJD, and to
rapidly identify any cases of vCJD which might occur in people in
Australia who were exposed to the disease in Europe. This is being
achieved through the National CJD Case Registry (based at the
Department of Pathology, University of Melbourne, and funded by the
Commonwealth Department of Health and Aged Care). The CJD Case
Registry also provides a diagnostic service for interpretation of
brain tissue samples and a western blot test of the 14-3-3
phosphoprotein, which is present in all nerve cells and released into
the extracellular space when the cells degenerate. It is measured in
cerebral spinal fluid and has proven utility in the clinical
diagnosis of classical forms of CJD.5 The CJD Case Registry is also
able to examine tonsil and other lymphoid tissues, which may be
biopsied for the diagnosis of vCJD, and to provide genetic tests for
mutations and susceptibility for the PrPSc-related gene.
Of paramount importance is safety of the Australian blood supply.
Concern about the risk of transmitting vCJD through blood and blood
products has been rising steadily, culminating with the disclosure
of infectivity in the blood of a sheep, which occurred halfway through
the incubation period after it had been experimentally infected with
BSE.6
Although no case of either classical or variant CJD has yet been linked
to contamination of blood or blood product,7 the propensity for
PrPSc to accumulate in the
lymphoreticular system, coupled with the experimental
demonstration of infectivity in blood,8 was sufficient to convince
the Australian regulatory authorities to introduce a deferral of
donations of blood from people who have lived in the United Kingdom for
more than six months between 1980 and 1996. Six months was chosen by US
authorities as an arbitrary interval calculated to balance
reduction in risk and preserving sufficient blood donors so as not to
jeopardise the blood supply. Currently, questions have been raised
about extending the donor deferral to residents of other European
countries with an emerging BSE problem.
The physicochemical inactivation profile of vCJD differs
significantly from classical CJD. While in both types of diseases the
infectious agent is likely to consist entirely of the PrPSc protein, the differing conformations of
the protein may be the reason why the vCJD agent is more resistant to
heat inactivation. As further tests on this are carried out, it may
become necessary to modify current recommendations for
decontamination of surgical instruments. Combining heat (134ºC)
with some form of chemical inactivation (1 mol/L NaOH) may prove to be
the only effective measure to assure complete sterilisation. These
measures are likely to be introduced into the United Kingdom for
instruments used at critical sites (brain, eyes, lymphoid tissue),
together with increased use of disposable instruments. Australian
authorities will need to make an independent assessment of this risk,
and then implement appropriate measures.
To assist in this process, a National Health and Medical Research
Council Expert Committee has been formed, and one of its immediate
tasks is an analysis of risk associated with imported European beef
products (eg, canned corned beef). Concurrently, the federal Chief
Medical Officer has announced that these products have been
suspended from importation and are to be removed from the food supply
pending an analysis of any BSE-related risk. The risk from non-food
items such as cosmetics and pharmaceuticals will be carefully
re-evaluated.
Another lesson from the past comes from the largest outbreak of
scrapie in sheep in the 1940s, which was caused by contamination of a
vaccine (for louping-ill virus -- a tick-borne flavivirus causing
encephalomyelitis, principally in sheep).9 It would therefore be
prudent to monitor carefully the quality of vaccines prepared for
both bovine and human use in the event that they might contain trace
amounts of the infectious BSE agent. The recent recall in Ireland of a
batch of oral poliovirus vaccine, in which human plasma albumin had
been sourced from a pool including a donor who subsequently developed
vCJD, highlights the sensitivity of this issue.10 Although the
risks must have been incalculably small, it is clear that the UK
regulatory authorities were not prepared to declare the risk
negligible. This situation epitomises the difficulties in risk
management when the absolute levels of risk are unknown, and are
likely to remain unknown for the foreseeable future.
A decade or more from now, we will be able to look back with hindsight and
determine whether the correct decisions were made. A judicial
inquiry into the BSE epidemic in the United Kingdom has now been
through this exercise, and delivered a valuable appraisal of how
government, its advisory committees, and the scientific research
community conducted the process of risk assessment, management and
communication.11 To their credit,
veterinary researchers rapidly identified the nature and probable
causes of the BSE epidemic within a year of its recognition, and the UK
government acted swiftly to break the cycle of bovine-to-bovine
transmission. However, serious deficits were identified in the way
that government managed the process of assessment, management and
communication of the risk to human health. In the 10-year interval
between the identification of BSE and the realisation of the
emergence of vCJD, the repeated warnings of medical scientific
advice were not adequately managed or communicated to the general
public.12 The disastrous
consequences of these failures (loss of public confidence in the beef
industry, heightened suspicion of all matters related to
biotechnological manipulation of foods) will resonate for at least
the next decade.
The most pressing need for Australia right now is to ensure that all
reasonably practical precautions for risk minimisation are
implemented and adequately communicated to the public. Research
into better methods of diagnosis and therapeutic strategies should
be encouraged. Vigilant surveillance for all forms of CJD should be
continued in the expectation that epidemiological risk factors will
be elucidated. Australia, once again geographically remote from the
epicentre of a major infectious calamity, may be in a prime position to
answer critical questions such as cumulative dose effects and
incubation periods within members of its population who have been
exposed to BSE. We can learn a great deal from the hard lessons which
have been visited upon our European colleagues.
Colin L Masters
Department of Pathology, University of Melbourne Melbourne, VIC
and the Mental Health Research Institute of Victoria
c.mastersATunimelb.edu.au
- Farquhar J, Gajdusek DC, editors. Kuru: early letters and
field-notes from the collection of D Carleton Gajdusek. New York:
Raven Press, 1981: 338 pp.
-
Will RG, Zeidler M, Stewart GE, et al. Diagnosis of new variant
Creutzfeldt-Jakob disease. Ann Neurol 2000; 47: 575-582.
-
Andrews NJ, Farrington CP, Cousens SN, et al. Incidence of variant
Creutzfeldt-Jakob disease in the UK. Lancet 2000; 356:
481-482.
-
Donnelly CA. Likely size of the French BSE epidemic.
Epidemiological analysis helps in evaluating the potential risks of
eating French beef. Nature 2000; 408: 787-788.
-
Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3-3
proteins as aids to the diagnosis of Creutzfeldt-Jakob disease.
Neurology 2000; 55: 811-815.
-
Houston F, Foster JD, Chong A, et al. Transmission of BSE by blood
transfusion in sheep. Lancet 2000; 356: 999-1000.
-
Wilson K, Code C, Ricketts MN. Risk of acquiring Creutzfeldt-Jakob
disease from blood transfusions: systematic review of case-control
studies. BMJ 2000; 321: 17-19.
-
Kuroda Y, Gibbs J, Amyx HL, Gajdusek DC. Creutzfeldt-Jakob disease
in mice: persistent viraemia and preferential replication of virus
in low-density lymphocytes. Infect Immun 1983; 41: 154-161.
-
Gordon WS. Advances in veterinary research. Louping-ill,
tick-borne fever and scrapie. Vet Rec 1946; 58: 516-520.
-
Birchard K. Concern over vCJD donor in polio-vaccine pool in
Ireland. Lancet 2000; 356: 2167.
-
Phillips [Lord], Bridgeman J, Ferguson-Smith M. The BSE Inquiry:
report, evidence and supporting papers of the Inquiry into the
emergence and identification of bovine spongiform encephalopathy
(BSE) and variant Creutzfeldt-Jakob Disease (vCJD) and the action
taken in response to it up to 20 March 1996. Vol 1: Findings and
conclusions. London: The House of Commons. The Stationery Office,
2000: 308 pp. (HC 887-I.)
-
Aldhous P. Inquiry blames missed warnings for scale of Britain's
BSE crisis. Nature 2000; 408: 3-5.
©MJA 2001
Readers may print a single copy for personal use. No further
reproduction or distribution of the articles
should proceed without the permission of the publisher. For
permission, contact the
Australasian Medical Publishing Company.
Journalists are welcome to write news stories based on what they read here, but should acknowledge their source as "an article published on the Internet by The Medical Journal of Australia <http://www.mja.com.au>".
<URL: http://www.mja.com.au/>
© 2001 Medical Journal of Australia.
|